Donation data reported on websites by drug makers and patient advocacy groups in Canada that receive industry funding is “haphazard, inconsistent and incomplete,” underscoring the difficulties in deciphering the influence these companies may have on patient interests, a new analysis finds.
Specifically, information about the value of donations made by drug companies, the years in which contributions were given, and the percent of income the money represented for patient groups was limited. Consequently, donations made and received often could not be matched, according to the analysis in the International Journal of Health Policy and Management.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
